The influence of target protein half-life on the effectiveness of antisense oligonucleotide analog-mediated biologic responses

Antisense and Nucleic Acid Drug Development

Volumn 8, Issue 4, 1998, Pages 281-293

  Spiller, D G ^a   Giles, R V ^a   Broughton, C M ^a   Grzybowski, J ^a   Ruddell, C J ^a   Tidd, D M ^a   Clark, R E ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; BCR ABL PROTEIN; BIOLOGICAL RESPONSE MODIFIER; CHIMERIC PROTEIN; MESSENGER RNA; MUTANT PROTEIN; PROTEIN P53; RIBONUCLEASE H; STREPTOLYSIN O;

ARTICLE; BONE MARROW PURGING; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CODON; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; HALF LIFE TIME; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN TARGETING; TARGET CELL;

EID: 0031715435     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.1.1998.8.281     Document Type: Article

References (15)

1. BARRY, E.L.R., GESEK, F.A., and FRIEDMAN, P.A. (1993). Introduction of antisense oligonucleotides into cells by permeabilization with streptolysin O. Bio Techniques 15, 1016-1020.
2. BEIMLING, P., BENTER, T., SANDER, T., and MOELLING, K. (1985). Isolation and characterization of the human cellular myc gene product. Biochemistry 24, 6349-6355.
3. BENNETT, C.F., CHIANG, M., CHAN, H., SHOEMAKER, J.E.E., and MIRABELLI, C.K. (1992). Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligodeoxynucleotide. Mol. Pharmacol. 41, 1023-1033.
4. BERGAN, R., CONNELL, Y., FAHMY, B., and NECKERS, L. (1993). Electroporation enhances c-myc antisense oligodeoxynucleotide efficacy. Nucleic Acids Res. 21, 3567-3573.
5. BERGAN, R., HAKIM, F., SCHWARTZ, G.N., KYLE, E., CEPADA, R., SZABO, J.M., FOWLER, D., GRESS, R., and NECKERS, L. (1996). Electroporation of synthetic oligodeoxynucleotides - A novel technique for ex-vivo bone-marrow purging. Blood 88, 731-741.
6. BROUGHTON, C.M., SPILLER, D.G., PENDER, N., KO-ROVSKAYA, M., GRZYBOWSKI, J., GILES, R.V., TIDD, D.M., and CLARK, R.E. (1997). Preclinical studies of streptolysin-O in enhancing antisense oligodeoxynucleotide uptake in harvests from chronic myeloid leukemia patients. Leukemia 11, 1435-1441.
7. CHOMCZYNSKI, P., and SACCHI, N. (1987). Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162, 156-159.
8. CLARK, R.E., GRZYBOWSKI, J., PENDER, N., SPILLER, D.G., BROUGHTON, C.M., BRAMMER, C., and TIDD, D.M. (1997). Transplantation of antisense oligodeoxynucleotide purged autografts in chronic myeloid leukemia. Exp Hematol 25, 781 (abstr).
9. DHUT, S., CHAPLIN, T., and YOUNG, B.D. (1990). BCR-ABL and BCR proteins: Biochemical characterization and location. Leukemia 4, 745-750.
10. EVAN, G.I., LEWIS, G.K., RAMSAY, G., and BISHOP, J.M. (1985). Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol. Cell. Biol. 5, 3610-3616.
11. FLANIGAN, W.M., KOTHAVALE, A., and WAGNER, R.W. (1996). Effects of oligonucleotide length, mismatches and mRNA levels on C-5 propyne-modified antisense potency. Nucleic Acids Res. 24, 2936-2941.
12. GILES, R.V., GRZYBOWSKI, J., SPILLER, D.G., and TIDD, D.M. (1997). Enhanced antisense effects resulting from an improved streptolysin O protocol for oligodeoxynucleotide delivery into human leukemia cells. Nucleotides Nucleosides 16, 1155-1163.
13. STEIN, C.A., and NARAYANAN, R. (1996). Antisense oligodeoxynucleotides - Internalization. Perspect. Drug Discovery and Des. 4, 41-50.
14. STEIN, C.A., SUBASINGHE, C., SHINOZUKA, K., and COHEN, J.S. (1988). Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res. 16, 3209-3221.
15. WAGNER, R.M. (1994). Gene inhibition using antisense oligodeoxynucleotides. Nature 372, 333-335.